No Data
No Data
No Data
No Data
No Data
Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
ROCKVILLE, Md., April 24, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous
GlobeNewswireApr 24 16:05 ET
Analysts' Opinions Are Mixed on These Healthcare Stocks: Argenx Se (ARGX), Neogen (NEOG) and Supernus Pharmaceuticals (SUPN)
TipRanksApr 15 07:10 ET
Supernus Pharmaceuticals Shares Slip 6.9% After FDA Says Drug Application Not Ready
By Ben Glickman Shares of Supernus Pharmaceuticals dropped Monday after regulators determined the company's new drug application was not ready for approval. The stock was down 6.9% to $31.23 in afte
WSJApr 8 13:49 ET
Supernus' Investigational Drug Application for Parkinson's Apomorphine Pump Suffers FDA Setback; Shares Fall Premarket
Supernus Pharmaceuticals (SUPN) said Monday the Federal Drug Administration had issued a Complete Response Letter in response to its new drug application for SPN-830, a setback for the investigational
MT NewswiresApr 8 09:17 ET
Supernus Stock Slides as FDA Rejects Parkinson's Disease Infusion Device
Seeking AlphaApr 8 08:39 ET
Express News | Supernus Pharmaceuticals Shares Are Trading Lower After the Company Announced the FDA Has Issued a Complete Response Letter in Response to the Company's New Drug Application for SPN-830
Moomoo 24/7Apr 8 08:20 ET
isaiahliloOP : FDA was damn fishy so I left before the drop hehe
Strike freedom : Don’t have akebia?
MeltyyOP Strike freedom: the first of the post
Strike freedom MeltyyOP: I mean in the April calendar
Srav Reddy : Wonder why $Akebia Therapeutics (AKBA.US)$ dropped after PDUFA
No Data
No Data
Ginvest : Thank you for the timely info